10 results about "Thrombotic disease" patented technology

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application provides a highland thrombosis disease risk early warning system, comprising: a sensing acquisition module, which is used for acquiring patient characteristic data, the patient characteristic data including physical sign data and individual baseline data; an index analysis module, which is used for preprocessing the patient characteristic data and generating risk indexes; a risk assessment module, which is used for assessing a risk coefficient according to the risk indexes; and a risk early warning module, which is used for obtaining a risk degree corresponding to the risk coefficient according to a pre-constructed risk classification standard, and implementing corresponding risk early warning according to the risk degree. The application solves the problem in the prior art that a portable health monitoring device cannot accurately measure core hemodynamic parameters closely related to thrombosis, and also cannot accurately perform risk early warning on highland thrombosis diseases according to the acquired parameters.

This disclosure relates to 5-amino-2,3-dihydro-1,4-phthalazinedione and its pharmaceutically acceptable salts for the prevention or treatment of thrombotic diseases. The invention particularly relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for this purpose. Pharmaceutical compositions, advantageous formulation techniques, and therapeutic methods are disclosed.

This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its enantiomer, diastereomer, transtransferase, racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain protein of Src kinase, interfering with the binding of integrin αIIbβ3 to Src kinase, thereby selectively inhibiting outward-to-inward signal transduction without affecting inward-to-outward signal transduction. This allows the compound of this invention to exert antithrombotic effects without affecting normal physiological hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of thrombosis-related cardiovascular and cerebrovascular diseases.

This invention discloses a sonodynamic synergistic thrombolysis system and its application. The system includes a tissue plasminogen activator variant, a sonosensitive agent, and an ultrasound source. The tissue plasminogen activator variant is an intravenously administered formulation, the sonosensitive agent is an intravenously infused formulation, and the ultrasound source is used to emit ultrasound during sonosensitive agent administration to activate the agent. This invention significantly improves thrombolysis efficiency and reduces thrombolytic agent dosage and bleeding risk through the dual synergistic effect of TNK-tPA enzymatic hydrolysis and sonodynamic chemical oxidation. The system can significantly improve vascular recanalization rate and blood flow velocity recovery rate, and has high biocompatibility. This invention is applicable to thrombolytic treatment of various thrombotic diseases and has the advantages of simple operation, strong targeting, and wide application range.

This invention relates to 2-phenylpyrimidine platelet aggregation inhibitors, their preparation methods, and their application in the preparation of drugs for treating thrombotic diseases, belonging to the field of pharmaceutical technology. The compounds of this invention, their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates have the structures shown in Formula I, wherein R1-R5 and A are as described in the claims and specification. The compounds of this invention, their pharmaceutically usable salts, tautomers, pharmaceutically usable solvates, and their pharmaceutical compositions have platelet aggregation inhibitory activity and can be used to prepare drugs for the prevention and treatment of thrombotic diseases.

The present invention relates to: a pharmaceutical composition for preventing or treating thrombotic diseases, the pharmaceutical composition comprising a compound of chemical formula 1 or an acceptable salt thereof; and a health functional food composition or cosmetic composition which is for improving blood circulation and comprises same Specifically, in the present invention, the compound of chemical formula 1 was found to simultaneously inhibit NOX1 and NOX2 and thus be highly effective in inhibiting platelet aggregation and thrombus formation.

The application belongs to the technical field of biological medicine, and particularly relates to a Buthus martensii Karsch (Buthus martensii Karsch) oligopeptide and application thereof in preparation of anti-platelet and anti-thrombus drugs or compositions. Buthus martensii The application discloses an anti-platelet oligopeptide discovered by combining an active-oriented separation with computer virtual screening based on a Karsch transcriptome database. The oligopeptide can not only inhibit platelet aggregation, but also effectively inhibit platelet adhesion and expansion. In a thrombus model experiment in vivo, the Buthus martensii Karsch oligopeptide discovered by the application can well inhibit FeCl3-induced carotid artery thrombosis of a mouse. Meanwhile, it is found that the Buthus martensii Karsch oligopeptide does not have obvious bleeding tendency. In conclusion, the Buthus martensii Karsch oligopeptide can be used as an anti-platelet aggregation and anti-thrombus drug to play a certain positive role in the prevention and treatment of thrombotic diseases.

The application relates to a preparation and application of an FXI targeting siRNA molecule and a GalNAC conjugate thereof. The siRNA molecule takes TN7 sequence as a core, is obtained through precise bioinformatics design and high-throughput screening, and has excellent gene silencing activity. Through systematic chemical modification optimization, the stability of the molecule is significantly improved. More importantly, the TN7-GalNAC conjugate exhibits an unprecedented persistent inhibitory effect in a mouse in-vivo experiment, and the FXI protein level is maintained below 10% of the basic level within 28 days after single administration. The application provides a new molecular tool for precise treatment of thrombotic diseases, and has important clinical application value.